Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa
N. Sarita Shah , Jessica Richardson, Prashini Moodley, Salona Moodley, Palav Babaria, Melissa Ramtahal, Scott K. Heysell, Xuan Li, Anthony P. Moll, Gerald Friedland, A. Willem Sturm, and Neel R. Gandhi
Author affiliations: Author affiliations: Tugela Ferry Care and Research Collaboration, Tugela Ferry, South Africa (N.S. Shah, J. Richardson, P. Babaria, S.K. Heysell, A.P. Moll, G. Friedland, N.R. Gandhi); Albert Einstein College of Medicine, Bronx, New York, USA (N.S. Shah, J. Richardson, X. Li, N.R. Gandhi); Montefiore Medical Center, Bronx (N.S. Shah, J. Richardson, X. Li, N.R. Gandhi); Nelson R. Mandela School of Medicine, Durban, South Africa (P. Moodley, S. Moodley, M. Ramtahal, A.W. Sturm); Yale University, New Haven, Connecticut, USA (P. Babaria, G. Friedland); Philanjalo Care Center, Tugela Ferry (A.P. Moll)
Figure 1. Drug resistance among extensively drug-resistant tuberculosis isolates from Tugela Ferry, South Africa, 2005–2009: 4-drug resistance = isoniazid (INH), rifampin (RIF), ofloxacin (OFL), and kanamycin (KM); 5-drug resistance = INH, RIF, OFL, KM, and ethambutol (EMB) or streptomycin (SM); 6-drug resistance = INH, RIF, OFL, KM, EMB, and SM. Column for 2008–2009 indicates study population.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.